MX2022015516A - Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2. - Google Patents

Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2.

Info

Publication number
MX2022015516A
MX2022015516A MX2022015516A MX2022015516A MX2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A
Authority
MX
Mexico
Prior art keywords
compounds
ethynylpyridine
derivatives useful
gcn2
inhibitors
Prior art date
Application number
MX2022015516A
Other languages
English (en)
Spanish (es)
Inventor
Gavin WHITLOCK
Matthew Fuchter
Original Assignee
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2Ipo Innovations Ltd filed Critical Ip2Ipo Innovations Ltd
Publication of MX2022015516A publication Critical patent/MX2022015516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022015516A 2020-06-09 2021-06-09 Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2. MX2022015516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2008749.0A GB202008749D0 (en) 2020-06-09 2020-06-09 Novel compounds
PCT/GB2021/051428 WO2021250399A1 (en) 2020-06-09 2021-06-09 4-ethynylpyridine derivatives useful as gcn2 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015516A true MX2022015516A (es) 2023-03-22

Family

ID=71616023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015516A MX2022015516A (es) 2020-06-09 2021-06-09 Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2.

Country Status (12)

Country Link
US (2) US20230271939A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161915A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023529926A (cg-RX-API-DMAC7.html)
KR (1) KR20230058042A (cg-RX-API-DMAC7.html)
CN (2) CN116113629B (cg-RX-API-DMAC7.html)
AU (1) AU2021289535A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181909A1 (cg-RX-API-DMAC7.html)
GB (1) GB202008749D0 (cg-RX-API-DMAC7.html)
IL (1) IL298860B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022015516A (cg-RX-API-DMAC7.html)
WO (1) WO2021250399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
GB202104635D0 (en) 2021-03-31 2021-05-12 Imperial College Innovations Ltd Methods and compositions for identifying and treating GCN2-dependent cancers
GB202118096D0 (en) * 2021-12-14 2022-01-26 Ip2Ipo Innovations Ltd Novel compounds
GB202403113D0 (en) 2024-03-04 2024-04-17 Apollo Ap30 Ltd Novel compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2006082371A1 (en) 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having tie2 (tek) inhibitory activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US9409914B2 (en) 2012-01-28 2016-08-09 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
EP2822948B1 (en) 2012-03-07 2016-04-06 Merck Patent GmbH Triazolopyrazine derivatives
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
CA2903903C (en) 2013-03-05 2021-05-04 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN105732614B (zh) 2014-12-09 2018-06-12 中国科学院广州生物医药与健康研究院 磺酰胺基芳基炔类化合物及其用途
CN104829613B (zh) 2015-04-13 2020-06-09 赤峰蒙广生物科技有限公司 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用
PL3498693T3 (pl) * 2016-08-10 2025-03-24 Takeda Pharmaceutical Company Limited Związek heterocykliczny
WO2018068739A1 (zh) 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物
CA3089762A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
AU2019212969B2 (en) * 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
US20230128972A1 (en) 2020-01-31 2023-04-27 Atomwise Inc. Anat Inhibitors and Methods of Use Thereof
EP4107146A1 (en) 2020-02-17 2022-12-28 Alesta Therapeutics BV Gcn2 modulator compounds
WO2021222147A1 (en) 2020-04-27 2021-11-04 Hibercell, Inc. Heterocyclic gcn2 modulators
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
KR20240021143A (ko) 2021-01-22 2024-02-16 히버셀, 인크. Gcn2 조정 화합물 및 그의 용도
US20240150345A1 (en) 2021-01-22 2024-05-09 Hibercell, Inc. Gcn2 modulating compounds and uses thereof

Also Published As

Publication number Publication date
KR20230058042A (ko) 2023-05-02
IL298860B2 (en) 2026-08-01
GB202008749D0 (en) 2020-07-22
EP4161915A1 (en) 2023-04-12
WO2021250399A1 (en) 2021-12-16
IL298860A (en) 2023-02-01
BR112022025147A2 (pt) 2023-04-25
IL298860B1 (en) 2026-04-01
US20230250082A1 (en) 2023-08-10
CN119661503A (zh) 2025-03-21
US20230271939A1 (en) 2023-08-31
US11945799B2 (en) 2024-04-02
JP2023529926A (ja) 2023-07-12
AU2021289535A1 (en) 2023-02-09
CN116113629B (zh) 2024-12-31
CA3181909A1 (en) 2021-12-16
CN116113629A (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
MX2024013721A (es) Inhibidor de gcn2
GEAP202215475A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PH12020551305A1 (en) Pharmaceutical Compounds
MX2023012054A (es) Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion.
MX2024006681A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12018500610B1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
TW200833675A (en) Nicotinamide derivatives
NZ748946A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2016015005A (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1.
MY194116A (en) Pharmaceutical compounds
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
WO2021016256A3 (en) Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
MX2025004213A (es) Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
BR112022025147A2 (pt) Derivados de 4-etinilpiridina úteis como inibidores de gnc2